Bhattacharjee J, El-Sayeh HG: Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2008;16(3):CD006617.
Caccia S et al: A new generation of antipsychotics: Pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag 2013;9:319.
Chue P: Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: Focus on the glycine transporter 1 (GlyT1). Curr Pharm Des 2013;19:1311.
Citrome L: A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: An evidence-based medicine approach. CNS Drugs 2013;27:879.
Citrome L: Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013;9:193.
Citrome L: Cariprazine in bipolar disorder: Clinical efficacy, tolerability, and place in therapy. Adv Ther 2013;30:102.
Citrome L: Cariprazine in schizophrenia: Clinical efficacy, tolerability, and place in therapy. Adv Ther 2013;30:114.
Correll CU et al: Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophr Res 2016;174:82.
Coyle JT: Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell Mol Neurobiol 2006;26:365.
Durgam S et al: An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry 2016;173:271.
Durgam S et al: Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placeboand active-controlled trial. J Clin Psychiatry 2015;76:e1574.
Escamilla MA, Zavala JM: Genetics of bipolar disorder. Dialogues Clin Neurosci 2008;10:141.
Fava M et al: Adjunctive brexpiprazole in patients with major depressive disorder and irritability: an exploratory study. J Clin Psychiatry 2016;77:1695.
Fountoulakis KN, Vieta E: Treatment of bipolar disorder: A systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008;11:999.
Freudenreich O, Goff DC: Antipsychotic combination therapy in schizophrenia: A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323.
Glassman AH: Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005;66(Suppl 6):5.
Grunder G, Nippius H, Carlsson A: The “atypicality” of antipsychotics: A concept re-examined and re-defined. Nat Rev Drug Discov 2009;8:197.
Haddad PM, Anderson IM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649.